Core Insights - Ace investor Mukul Mahavir Agrawal reshuffled his Rs 6,500-crore equity portfolio during the December quarter, reflecting a mix of fresh bets and tactical adjustments following sharp stock-specific corrections and a selloff in smallcap stocks in 2025 [18] Company Summaries - **Hindustan Construction**: Agrawal acquired a 1.68% stake, amounting to 4.40 crore shares, after the stock experienced a correction of over 30% in the past year [1] - **Alcargo Logistics**: Agrawal purchased a 2.9% stake in the company, which has seen a decline of about 80% over the last year. Alcargo specializes in integrated logistics services [2] - **Sudeep Pharma**: A 1.3% stake was acquired by Agrawal, with the stock down nearly 30% in the last year. Sudeep is a manufacturer of mineral-based pharmaceutical excipients and specialty ingredients [3] - **Vasa Denticity**: Agrawal increased his stake by 0.4%, bringing his total holding to 2.4%. The company is a leading B2B e-commerce platform for dental products [4] - **Vikran Engineering**: Agrawal increased his stake by 0.2%. The stock is down 10% from its issue price of Rs 97 since its market debut in September last year [7] - **N R Agrawal**: A marginal stake increase of 0.1% was made, with the stock down nearly 20% from its 52-week high of Rs 514 [8] - **Monolithisch**: Agrawal reduced his stake by 0.2% to 2.76%, with the stock down 20.5% from its 52-week high of Rs 607 [9] - **Pearl Global**: The investor offloaded 0.2% in the company, which has fallen nearly 15% in January alone [10] - **InfoBeans Technologies**: Agrawal reduced his stake by 0.2% to 3.9%, with the stock up 97% in the last year [11] - **Autoriders**: A stake reduction of 0.7% occurred, with the stock rising over 1,100% in the last year [12] - **Zota Healthcare**: Agrawal reduced his stake by 0.8%, with the stock up nearly 40% in the last year [13] - **ASM Technologies**: A stake reduction of 0.4% was noted, with the stock having doubled in the last year, rising about 115% [14] - **Stanley Lifestyles**: Agrawal appears to have exited the stock, which is down nearly 50% in the last year [15]

Core Insights - Premier Graphene Inc. has secured COFEPRIS authorization, allowing its partners to import, register, and commercialize CBD, CBG, and other cannabinoid products in Mexico [3][5][6] Group 1: Regulatory Milestone - The authorization from COFEPRIS enables the importation and commercialization of a wide range of hemp-derived products, including CBD and CBG extracts, cosmetics, and nutraceuticals [6][7] - HGI Industrial Technologies and Santa Rosa Green Seeds have received an official importing license, marking a significant regulatory achievement for the company [5][11] Group 2: Market Expansion - This approval opens pathways for growth in Mexico and the broader Latin American wellness and industrial sectors, enhancing Premier Graphene's strategic diversification [4][10] - The company aims to expand its market reach beyond Mexico to Belize and the Caribbean islands [10] Group 3: Military and Industrial Applications - The authorization positions Premier Graphene to secure military contracts, allowing for cost-effective production of advanced protective gear utilizing graphene [8][9] - The company is committed to meeting the needs of defense and technology sectors while enhancing graphene supply chains [11]

Core Viewpoint - KRTL Holding Group Inc. has completed a PCAOB audit of its financial statements for the years ended December 31, 2024, and 2023, with no changes to previously reported unaudited amounts, and reported financial results for the three and nine months ended September 30, 2025, including contributions from its newly acquired subsidiary, Sigma [1][2][4]. Financial Performance - For the three months ended September 30, 2025, total revenues amounted to $1,815,781, with $1,752,656 generated from 28 days of operations of the Sigma subsidiary [2]. - Sigma generated approximately $19.7 million in revenue with a gross margin of 57% for the six months ended September 30, 2025, indicating an annualized revenue run rate of about $40 million [3]. Asset and Equity Position - As of September 30, 2025, KRTL Holding Group reported total assets of approximately $23.8 million and total shareholders' equity of $8.7 million [4]. Strategic Initiatives - The acquisition of Sigma is viewed as a scalable revenue base, with plans to expand distribution of pharmaceuticals and nutraceuticals internationally, including a potential entry into the U.S. market [3]. - The completion of the PCAOB audit positions the Company to pursue an uplisting to a higher-tier trading venue, which could enhance visibility and improve trading liquidity [4]. Company Overview - KRTL Holding Group operates through subsidiaries KRTL Biotech, Inc. and KRTL International Corp., leveraging strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value [6].

Core Insights - Ashland Inc. reported its fourth-quarter financial results for fiscal year 2025, showing a disciplined approach to navigating challenging market conditions while maintaining strong margins and delivering results in line with expectations [1][2][3] Financial Performance - Fourth-quarter sales were $478 million, down 8% from $522 million in the prior-year quarter, with Portfolio Optimization initiatives reducing sales by approximately $38 million, or 7% [4][21] - Net income was $32 million, up from $16 million in the prior year, with income from continuing operations at $33 million, compared to $19 million [3][4] - Adjusted EBITDA was $119 million, representing a 25% margin, down 4% from $124 million in the prior-year quarter, primarily due to a reduction from Portfolio Optimization [3][4][24] Segment Performance - **Life Sciences**: Sales totaled $173 million, down 10% year-over-year, primarily due to Portfolio Optimization initiatives, with pharma demand showing resilience and low-single-digit sales growth [9][10][11] - **Personal Care**: Sales were $151 million, a decrease of 7% compared to the prior year, but excluding divestiture impacts, the segment delivered 5% sales growth [12][15] - **Specialty Additives**: Sales were $131 million, down 9% year-over-year, with performance stability in Europe and Latin America despite challenges in North America and MEAI [16][17] - **Intermediates**: Sales totaled $33 million, down 8% year-over-year, driven by lower pricing and merchant volumes [18][19] Fiscal Year 2025 Summary - Total sales for fiscal year 2025 were $1.824 billion, down 14% from the prior year, with Portfolio Optimization initiatives reducing sales by approximately $208 million [21][24] - Net loss was $845 million, primarily due to non-cash impairments, with adjusted income from continuing operations at $157 million, down from $224 million [23][24] - Cash flow from operating activities totaled $134 million, down from $462 million in the prior year, reflecting changes in working capital and lower earnings [25] Fiscal Year 2026 Outlook - Sales guidance for fiscal 2026 is projected between $1.835 billion and $1.905 billion, reflecting organic growth of approximately 1% to 5% [29][30] - Adjusted EBITDA is expected to be between $400 million and $430 million, with ongoing free cash flow conversion targeted at approximately 50% of adjusted EBITDA [29][30] - The company remains focused on executing its strategic priorities, including cost management and innovation-driven growth [34][32]